By activating downstream arousal pathways of OX2R, these agonists not only simultaneously improve EDS, cataplexy, and nocturnal sleep fragmentation, but also enhance overall wakefulness quality—including heightened attention and reduced anxiety. The gene discussed is HCRTR2; the disease is Cataplexy.